Peer-reviewedCC BYAdvanced Science
ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer
5 affiliations
- 1the First Hospital and College of Basic Medical Sciences of China Medical University
- 2Tianjin Medical University General Hospital
- 3Shengjing Hospital of China Medical University
- 4First Hospital of China Medical University
- 5the First Hospital of China Medical University
Related
- Baicalein Synergizes with Docetaxel in TNBC and the Combination Suppresses AKT/GSK3β/β-Catenin Signaling
- IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer
- HDAC6 inhibition reverts docetaxel resistance in castration resistant prostate cancer
- PADI2 facilitates progression and cisplatin resistance of epithelial ovarian cancer via m6A methylation
- TMEM55B Maintains Lysosomal Homeostasis and Promotes ER–Lysosome Calcium Signaling
BibTeX
@article{gan2026zmiz2dux4lgr5,
title = {{ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer}},
author = {Xueting Gan and Shulei Sun and Ran Hu and Yuheng Feng and Xinhao Wu and Fangqi Liu and Xuyong Lin and Xiupeng Zhang and Xuezhu Rong and Qiang Han},
journal = {Advanced Science},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13691226},
note = {CC BY},
}
RIS
TY - JOUR
TI - ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer
AU - Xueting Gan
AU - Shulei Sun
AU - Ran Hu
AU - Yuheng Feng
AU - Xinhao Wu
AU - Fangqi Liu
AU - Xuyong Lin
AU - Xiupeng Zhang
AU - Xuezhu Rong
AU - Qiang Han
PY - 2026
DA - 2026/10/22
JO - Advanced Science
UR - https://europepmc.org/article/PMC/PMC13691226
SN - 2198-3844
ER -